ERAP1 and neoplasm: The immune response escape of tumor cells by the imbalance of ERAP2/ERAP1 was further supported by prior studies [101,102], in which a decreased HLA class 1 surface expression was observed together with this imbalance, thereby reducing the tumor-associated peptide antigen presentation.